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ABSTRACT Pulmonary hypertension (PH) is a life-shortening condition characterised by episodes of
decompensation precipitated by factors such as disease progression, arrhythmias and sepsis. Surgery and
pregnancy also place additional strain on the right ventricle. Data on critical care management in patients
with pre-existing PH are scarce.
We conducted a retrospective observational study of a large cohort of patients admitted to the critical
care unit of a national referral centre between 2000–2017 to establish acute mortality, evaluate predictors
of in-hospital mortality and establish longer term outcomes in survivors to hospital discharge.
242 critical care admissions involving 206 patients were identified. Hospital survival was 59.3%, 94%
and 92% for patients admitted for medical, surgical or obstetric reasons, respectively. Medical patients had
more severe physiological and laboratory perturbations than patients admitted following surgical or
obstetric interventions. Higher APACHE II (Acute Physiology and Chronic Health Evaluation) score, age
and lactate, and lower oxygen saturation measure by pulse oximetry/inspiratory oxygen fraction (SpO2/FiO2)
ratio, platelet count and sodium level were identified as independent predictors of hospital mortality. An
exploratory risk score, OPALS (oxygen (SpO2/FiO2) ⩽185; platelets ⩽196×10
9·L−1; age ⩾37.5 years; lactate
⩾2.45 mmol·L−1; sodium ⩽130.5 mmol·L−1), identified medical patients at increasing risk of hospital
mortality. One (11%) out of nine patients who were invasively ventilated for medical decompensation and
50% of patients receiving renal replacement therapy left hospital alive. There was no significant difference
in exercise capacity or functional class between follow-up and pre-admission in patients who survived to
discharge.
These data have clinical utility in guiding critical care management of patients with known PH. The
exploratory OPALS score requires validation.
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Critical care survival is worse in PH patients admitted for medical rather than surgical/obstetric
indications. Nevertheless, many show longer term survival and functional recovery. Markers of
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Pulmonary hypertension (PH) describes a group of conditions characterised by the presence of a mean
pulmonary arterial pressure ⩾25 mmHg [1]. Increase in right ventricular (RV) afterload results in right
ventricular impairment with subsequent reduced exercise capacity, RV failure and premature death [2, 3].
Pulmonary vasodilator medical therapy and pulmonary endarterectomy surgery have been demonstrated
to improve long-term outcomes in patients with group 1 (pulmonary arterial hypertension; PAH) and
group 4 disease (chronic thromboembolic PH; CTEPH), respectively [4, 5].
Despite these advances in treatment, PH is still a life-shortening condition with a propensity for episodes
of decompensation precipitated by factors such as disease progression, arrhythmias and sepsis [6, 7].
Surgery and pregnancy also place additional strain on the RV and are associated with increased mortality
and morbidity [8–10]. As such, patients with PH may require treatment on the critical care unit during
the course of their disease [6]. There are relatively few published papers regarding critical care outcomes
for PH patients. These are often limited by sample size [11–14] or lack of data granularity [15].
We therefore conducted a retrospective observational cohort study of patients with known pre-existing PH
who had been admitted to the critical care unit (encompassing patients requiring general high dependency
or general intensive care beds) of a UK PH referral centre over a 17-year period, to establish acute
mortality, evaluate outcome predictors and define longer term outcomes.
Methods
Study design
Consecutive patients (aged ⩾16 years) in the ASPIRE registry [16] who had been managed on our critical
care units between April 2000 and December 2017 were identified by cross-referencing with two critical
care databases: the critical care clinical information system (MetaVision ICU; iMDsoft, Tel Aviv, Israel)
and the local Intensive Care National Audit and Research Centre case mix programme database. PH was
categorised according to the 5th World Symposium on Pulmonary Hypertension classification [17]. The
study was approved by both the UK Health Research Authority (HRA, IRAS no 246341) and the local
institutional review board (STH 20394) after independent scientific review.
Data
Critical care data collected included: patient demographics; admission circumstances (medical/surgical/
obstetric; planned versus unplanned); Acute Physiology and Chronic Health Evaluation II score (APACHE
II); routine physiological and laboratory parameters; treatment modalities (vasopressors, inotropes,
noninvasive ventilatory support, invasive positive pressure ventilation, renal replacement therapy (RRT));
critical care and hospital length of stay; and critical care and hospital mortality. APACHE II score and
physiological and laboratory parameters were taken at critical care admission. Longer term survival status
was ascertained at the censoring date of 31 December 2018 using data from the NHS Personal
Demographics Service to ensure at least 1-year follow-up for survivors. Where survival allowed it,
follow-up included 5-year data and beyond. In addition, we retrieved the following data from the ASPIRE
registry: PH classification, right heart catheter data (most recent prior to admission), World Health
Organization (WHO) functional class (FC) and incremental shuttle walk distance (ISWD) at baseline
(2 weeks to 18 months prior to admission) and at follow-up (nearest to 12 months post-discharge for
WHO FC, and nearest to 6 and 12 months post-discharge for ISWD).
Statistical analysis
Data were analysed using SPSS Statistics version 22. Quantitative data are described as mean±SD or median
(range or interquartile range) as appropriate. Normality of data was assessed using histograms and the
Kolmogorov–Smirnov test. Categorical data were analysed using the Chi-squared and Fisher’s exact test.
The paired samples t-test and related-samples Wilcoxon signed rank test were used to assess differences in
ISWD and WHO FC over time. Differences in length of stay between groups were examined with the
Kruskal-Wallis method. The association between admission characteristics and mortality was assessed
using univariate and multiple-variable logistic regression analysis. The latter was conducted with a
hierarchical approach using a pre-determined limited number of variables based on their biological and
clinical plausibility in light of the existing evidence base, having removed those with high collinearity or
significant missing data. Survival analysis was performed using the Kaplan–Meier method, log-rank testing
and Cox regression. Only first presentations to the intensive care unit (ICU) were taken into account for
survival analysis. Results are expressed as odds ratios or hazard ratios with 95% confidence intervals as
appropriate. Receiver operating characteristic analysis was used to identify optimal thresholds for hospital
survival. An exploratory risk score for medical patients, based on the number of adverse parameters using
these thresholds, was subsequently calculated. A p-value <0.05 was regarded as statistically significant
throughout.
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Results
Baseline characteristics
Overall, 242 consecutive critical care admissions in 206 individual patients were included in the study. The
median (min–max) age of the study population was 52.5 (17–87) years and 68% of patients were female.
The majority of patients had PAH (67%) or CTEPH (16%). Baseline characteristics are summarised in
table 1. 167 (69%) admissions were for medical reasons, followed by surgical and obstetric indications in
50 (21%) and 25 (10%) admissions, respectively. The commonest reasons for medical admissions were
right heart failure (38%) and respiratory failure and/or respiratory infection (26%). The majority of
surgical patients (84%) were elective admissions. Medical patients had a greater degree of physiological
and biochemical derangement on critical care admission compared with the surgical and obstetric cohorts,
exemplified by higher APACHE II scores, poorer oxygenation, worse renal and liver biochemistry and
higher C-reactive protein. Detailed patient characteristics on critical care admission are provided in table 2.
Acute mortality and length of stay
Overall, critical care and hospital survival rates were 78.5% and 69.8%, respectively. Medical patients had
lower hospital survival (59%) compared with their surgical (94%) or obstetric counterparts (92%; p<0.001
for medical versus surgical groups and p=0.006 for medical versus obstetric groups) (table 3). Crude
critical care, and hospital, 90-day and 1-year survival rates according to patient group, PH subtype and
critical care-specific therapies are provided in table 3. Unplanned admissions had lower hospital survival
than planned admissions (61.0% versus 93.8%, p<0.001). The median (min–max) length of stay in critical
care for medical, surgical and obstetric patients was 3.6 (0.02–36.9), 1.5 (0.7–10.8) and 3.2 (0.7–9.0) days,
respectively. The median (min–max) in-hospital length of stay (from critical care admission) for these
patient groups was 11.3 (0.02–108.0), 7.4 (0.9–68.2) and 9.0 (1.3–16.0) days. Medical patients had
significantly longer stays on critical care (p=0.004) and in hospital (p=0.041) when compared with their
surgical counterparts.
TABLE 1 Baseline characteristics
Subjects n 242
Age years 52.5 (17–87)
Female 68.2
PH diagnostic group
1 Pulmonary arterial hypertension 162 (66.9)
Idiopathic/heritable/drugs and toxins 96 (59.3)
Connective tissue disease associated 40 (24.7)
Congenital heart disease associated 18 (11.1)
Others 8 (4.9)
2 PH due to left heart disease 13 (5.3)
3 PH due to lung disease/chronic hypoxia 14 (5.8)
4 Chronic thromboembolic PH 39 (16.1)






ISWD m# 190 (0–1020)
Pulmonary haemodynamics¶
mRAP mmHg 10.0 (1–34)
mPAP mmHg 47 (14–74)
PAWP mmHg 10 (0–33)
CO L·min−1 4.7 (1.87–14.2)
CI L·min−1·m−2 2.6 (1.2–6.0)
PVR dyn·s−1·cm−5 561 (84–2400)
SvO2 % 65 (35–86)
Data are presented as median (min–max), % or n (%), unless otherwise stated. PH: pulmonary
hypertension; WHO: World Health Organization; ISWD: incremental shuttle walk distance; mRAP: mean
right atrial pressure; mPAP: mean pulmonary artery pressure; PAWP: pulmonary arterial wedge pressure;
CO: cardiac output; CI: cardiac index; PVR pulmonary vascular resistance; SvO2: mixed venous oxygen
saturations. #: 2 weeks to 18 months prior to admission; ¶: nearest prior to admission.
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Main reason for admission
Medical patients
Isolated heart failure 63 (37.7)
Respiratory failure/chest sepsis 44 (26.4)
Sepsis (other) 13 (7.8)





Peri-operative (planned): 42 (84)
Orthopaedic 18 (36)
Hernia repair 4 (8)
Other general surgery 7 (14)
Urological 3 (6)
Miscellaneous# 10 (20)








Other pregnancy related causes 6 (24)
Physiological parameters Medical¶ Surgical/obstetric+ p-value
APACHE II 15.0 (2–31) 10 (2–21) <0.001
Heart rate 99 (48–163) 80 (49–126) <0.001
mSAP mmHg 79 (41–140) 85 (56–117) 0.001
Respiratory rate 24 (12–52) 17 (9–39) <0.001
SpO2/FiO2 ratio 168 (68–467) 278 (108–467) <0.001
PaO2 kPa 10.4 (4.3–28.9) 13.7 (6.9–25.3) <0.001
PaO2/FiO2 ratio 22 (5–72) 49 (9–89) <0.001
CVP mmHg 18 (2–35) 8 (3–22) <0.001
Glasgow Coma Scale 15 (3–15) 15 (13–15) 0.010
pH 7.43 (6.98–7.54) 7.41 (7.31–7.51) 0.253
Base excess mmol·L−1 −2.6 (−20.4–26.9) −1.75 (−8.5–7.2) 0.219
Lactate mmol·L−1 1.2 (0.4–14.1) 1.0 (0.5–2.4) 0.006
Sodium mmol·L−1 135 (113–147) 138 (127–146) <0.001
Urea mmol·L−1 10.2 (2.5–59.4) 3.9 (1.2–16.1) <0.001
Creatinine μmol·L−1 117 (3–891) 61.5 (26–181) <0.001
Bilirubin μmol·L−1 17 (1–131) 11 (2–55) <0.001
AST IU·L−1 27 (6–4733) 18 (11–150) <0.001
CRP mg·L−1 38 (1–471) 11.6 (0.3–340) <0.001
Haemoglobin g·L−1 119 (53–204) 113 (86–166) 0.027
Platelets ×109·L−1 194 (32–859) 202 (73–448) 0.297
Data are presented as n (%) or median (min–max), unless otherwise stated. Comparisons made using
Mann–Whitney U-test, medical versus surgical/obstetric groups. PE: pulmonary embolism; APACHE II:
Acute Physiology and Chronic Health Evaluation II; mSAP: mean systemic arterial pressure; SpO2: oxygen
saturation measured by pulse oximetry; FiO2: inspiratory oxygen fraction; PaO2: arterial oxygen tension;
CVP: central venous pressure; AST: aspartate aminotransferase; CRP: C-reactive protein. #: neurosurgery,
spinal surgery, vascular, breast and gynaecological; ¶: n=167; +: n=75.
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Although a number of patients were on an active lung or heart/lung transplant list at the time of critical
admission, no patients were transferred directly for transplantation (with or without extracorporeal membrane
oxygenation). Hospital mortality was worse in the 48 medical admissions during 2000–2010 compared with
the 119 patients admitted subsequently (65% versus 31%, p<0.001). Although there was no significant
difference in age or most recent ISWD and FC between these two groups, median APACHE II score was
significantly higher in the earlier group (19 (range 16–22) versus 14 (10–19) in the latter group (p=0.005)).
Predictors of hospital mortality in the medical group
Univariate analysis for medical patients demonstrated a significant association with hospital mortality for
age, primary admission reason, APACHE II score and several physiological and biochemical markers on
admission (table 4). However, measures of pre-admission PH severity and functional state were not
significantly associated with acute mortality. In multivariate analysis of the medical patient cohort,
higher APACHE II score and lower serum sodium level were independent predictors of hospital
mortality (Model 1) (table 5). Since APACHE II score incorporates several of the selected variables and
may therefore mask their individual contribution, analysis was repeated (Model 2) (table 5) without
APACHE II. Higher age and serum lactate, and lower pulse oximetry/inspiratory oxygen fraction (SpO2/
FiO2) ratio and platelet count gained significance while low sodium retained its significant association
with mortality. When multivariate analysis was repeated for the entire study cohort (including surgical
and obstetric patients), the results mirrored those of the medical group alone (data for entire study
group not shown).
In-hospital mortality for medical patients, according to quintiles of the independent prognostic markers is
shown in figure 1. Area under the curve (AUC) and optimal threshold for predicting hospital mortality in
the medical patient group for each parameter were: APACHE II: 0.74 and ⩾13.5; SpO2/FiO2: 0.61 and ⩽185;
platelets: 0.59 and ⩽196×109·L−1; age: 0.64 and ⩾37.5 years; lactate: 0.63 and ⩾2.45 mmol·L−1; sodium:
0.60 and ⩽130.5 mmol·L−1. Hospital mortality in medical patients, based on the number of single risk
factors with adverse levels based on these thresholds (OPALS: oxygen (SpO2/FiO2), platelets, age, lactate and
sodium), is shown in figure 2. AUC for this OPALS score in medical patients was 0.78 with an optimal
threshold ⩾2.5.
Critical care interventions and mortality in the medical group
Compared with overall survival to hospital discharge in the medical group, the requirement for ventilatory
or cardiovascular support was associated with worse survival (table 3). One patient out of nine who was
TABLE 3 Critical care and hospital survival according to patient group and intensive care unit (ICU) therapy
N ICU survival Hospital survival 90-day survival 1-year survival N# 5-year survival#
Overall 242 190 (78.5) 169 (69.8) 158 (65.3) 132 (54.5) 146 45 (30.8)
Patient group
Medical 167 120 (71.9) 99 (59.3) 91 (54.5) 68 (40.7) 114 26 (22.8)
Surgical 50 47 (94.0) 47 (94.0) 45 (90) 42 (84) 19 10 (52.6)
Obstetric 25 23 (92.0) 23 (92.0) 22 (88) 22 (88) 13 9 (69.2)
PH group
1 PAH 162 127 (78.4) 115 (71.0) 107 (66.0) 90 (55.6) 95 32 (33.7)
2 PH due to left heart disease 13 11 (84.6) 10 (76.9) 10 (76.9) 8 (61.5) 7 2 (28.6)
3 PH due to lung disease/hypoxia 14 9 (64.3) 8 (57.1) 7 (50) 6 (42.9) 10 0 (0)
4 Chronic thromboembolic PH 39 34 (87.2) 29 (74.4) 27 (69.2) 24 (61.5) 26 10 (38.5)
5 Unclear/multifactorial 14 9 (64.3) 7 (50) 7 (50) 4 (28.6) 8 1 (12.5)
ICU therapy (medical patients only)
CPAP as highest level of ventilatory support 53 34 (64.1) 27 (50.9) 25 (47.1) 20 (37.7) 33 2 (6.1)
NPPV as highest level of ventilatory support 15 9 (60) 6 (40) 5 (33.3) 3 (20) 10 0 (0)
IPPV as highest level of ventilatory support 9 3 (33.3) 1 (11.1) 1 (11.1) 1 (11.1) 9 0 (0)
CRRT 22 17 (77.3) 11 (50.0) 9 (40.9) 7 (31.8) 20 5 (25)
Vasopressors received 49 23 (46.9) 16 (32.7) 15 (30.6) 11 (22.4) 28 3 (10.7)
Inotropes received 37 17 (45.9) 13 (35.1) 12 (32.4) 7 (18.9) 29 3 (10.3)
Prostaglandins (intravenous) received 113 78 (69.0) 68 (60.2) 61 (54) 45 (39.8) 73 18 (24.7)
Data are presented as n (%), unless otherwise stated. PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; CPAP: continuous
positive airway pressure; NPPV: non-invasive positive pressure ventilation: IPPV: invasive positive pressure ventilation; CRRT: continuous renal
replacement therapy. #: patients admitted prior to 31 December 2013 for whom 5 years of survival data is available.
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invasively ventilated survived to hospital discharge; however, this patient survived 17 months
post-discharge and was in WHO FC II at initial follow-up. 50% of the 22 patients who required RRT
survived to be discharged home.
TABLE 4 Medical patients: univariate predictors of hospital mortality
Variable N OR (95% CI) p-value
Age years 167 1.02 (1.01–1.04) 0.005
Female (ref.) 167 0.914 (0.481–7.738) 0.784
PH group 167 0.704
1 Pulmonary arterial hypertension Ref.
2 PH due to left heart disease 1.568 (0.303–8.120) 0.592
3 PH due to lung disease/hypoxia 1.307 (0.376–4.541) 0.674
4 Chronic thromboembolic PH 0.882 (0.359–2.169) 0.785
5 Unclear/multifactorial 2.195 (0.656–7.350) 0.202
Admission reason# 167 0.03
Heart failure Ref. Ref.
Respiratory failure/chest sepsis 0.554 (0.254–1.208) 0.138
Sepsis (other) 0.356 (0.099–1.277) 0.113
Pulmonary embolism 0.800 (0.150–4.274) 0.794
Arrhythmia 0.133 (0.028–0.646) 0.012
Renal failure 0.267 (0.066–1.079) 0.064
Other 0.200 (0.051–0.779) 0.020
ISWD 102 0.998 (0.995–1.001) 0.242
APACHE II 137 1.180 (1.095–1.270) <0.001
Heart rate 166 1.011 (0.995–1.028) 0.190
mSAP mmHg 163 0.983 (0.964–1.003) 0.100
Respiratory rate 167 1.046 (1.005–1.087) 0.026
SpO2 % 167 0.984 (0.939–1.030) 0.482
FiO2 165 5.896 (1.445–24.061) 0.013
PaO2 kPa 142 0.959 (0.888–1.036) 0.292
SpO2/FiO2 ratio 134 0.997 (0.993–1.001) 0.114
PaO2/FiO2 ratio 134 0.983 (0.959–1.008) 0.187
Central venous pressure mmHg 54 1.096 (1.021–1.177) 0.011
Glasgow Coma Scale 138 0.727 (0.539–0.980) 0.036
pH 148 0.007 (0.000–0.393) 0.016
Base excess mEq·L−1 147 0.933 (0.886–0.984) 0.01
Lactate mmol·L−1 141 1.425 (1.117–1.817) 0.004
Serum sodium mmol·L−1 157 0.937 (0.884–0.993) 0.027
Serum urea mmol·L−1 156 12.7 (4.37–80.2) 0.001
Serum creatinine µmol·L−1 155 1.005 (1.001–1.009) 0.013
Total bilirubin µmol·L−1 143 6.08 (2.97–19.8) 0.022
AST IU·L−1 123 0.999 (0.995–1.002) 0.456
CRP mg·L−1 141 1.005 (1.000–1.009) 0.054
Haemoglobin g·L−1 157 0.990 (0.978–1.003) 0.123
Platelets ×109·L−1 156 0.997 (0.994–1.000) 0.033
Right atrial pressure mmHg 109 1.044 (0.990–1.101) 0.108
Mean PAP mmHg 114 1.005 (0.973–1.037) 0.775
PAWP mmHg 102 1.000 (0.919–1.088) 1.000
Cardiac output L·min−1 110 0.909 (0.743–1.112) 0.352
Cardiac index L·min−1·m−2 104 0.838 (0.584–1.201) 0.335
PVR dyn·s−1·cm−5 99 1.000 (0.999–1.001) 0.482
SvO2 % 102 0.966 (0.929–1.005) 0.087
Variables either at most recent review prior to admission (Right heart catheter data, ISWD at 2 weeks to
18 months prior to admission) or at critical care admission (e.g. laboratory tests and physiological
observations). Bold indicates statistical significance. PH: pulmonary hypertension; ISWD: incremental
shuttle walking distance; APACHE II: Acute Physiology and Chronic Health Evaluation II; mSAP: mean
systemic arterial pressure; SpO2: oxygen saturation measured by pulse oximetry; FiO2: inspiratory oxygen
fraction; PaO2: arterial oxygen tension; AST: aspartate aminotransferase; CRP: C-reactive protein; PAP:
pulmonary artery pressure; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular
resistance; SvO2: mixed venous oxygen saturation.
#: main indication for critical care admission.
https://doi.org/10.1183/23120541.00046-2021 6
CRITICAL CARE | K. BAUCHMULLER ET AL.
TABLE 5 Medical patients: multivariate predictors of hospital mortality
Variable OR (95% CI) p-value
Model 1#
APACHE II per point 1.148 (1.052–1.253) 0.002
Sodium mmol·L−1 0.927 (0.864–0.996) 0.038
Platelets ×109·L−1 0.997 (0.993–1.000) 0.052
SpO2/FiO2 ratio 0.997 (0.992–1.001) 0.104
Bilirubin IU·L−1 0.997 (0.970–1.024) 0.806
Creatinine µmol·L−1 0.999 (0.995–1.004) 0.790
Lactate mmol·L−1 1.292 (0.983–1.700) 0.067
Model 2¶
Age years 1.045 (1.018–1.073) 0.001
Sodium mmol·L−1 0.901 (0.836–0.971) 0.007
Platelets ×109·L−1 0.996 (0.993–1.000) 0.038
SpO2/FiO2 ratio 0.995 (0.991–0.999) 0.020
Total bilirubin µmol·L−1 0.993 (0.966–1.021) 0.620
Creatinine µmol·L−1 1.002 (0.998–1.006) 0.333
Lactate mmol·L−1 1.562 (1.181–2.066) 0.002
APACHE II: Acute Physiology and Chronic Health Evaluation II; SpO2: oxygen saturation measured by pulse
oximetry; FiO2: inspiratory oxygen fraction.
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FIGURE 1 Histograms demonstrating in-hospital mortality in medical patients according to quintiles of
a) APACHE II (Acute Physiology and Chronic Health Evaluation II) score, b) platelet count, c) serum sodium
level, d) age, e) oxygen saturation measure by pulse oximetry (SpO2)/inspiratory oxygen fraction (FiO2) ratio and
f) lactate. Each bar represents 20% of the population for that parameter.
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Surgical and obstetric patients
Three (6%) out of 50 patients admitted following surgery died before hospital discharge. Two of the
patients had undergone expedited complex abdominal cancer surgery and one patient presented for an
emergency laparotomy. All three patients had severe cardio-respiratory comorbidities, two patients had
established multiple organ failure prior to surgery and one patient suffered an intra-operative
complication. Two out of 25 patients admitted for obstetric reasons died before hospital discharge; both
patients had severe PAH, one of whom had suboptimal compliance with PAH medications during
pregnancy while the other patient presented immediately following delivery with previously undiagnosed
PH. Both patients deteriorated despite aggressive management including intravenous prostanoid therapy.
FIGURE 2 OPALS score. Risk of
hospital mortality in medical
patients based on number of
adverse single risk factors. OPALS:
oxygen (oxygen saturation measured
by pulse oximetry/inspiratory oxygen
fraction ratio) ⩽185; platelets
⩽196×109·L−1; age ⩾37.5 years;
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6 8
FIGURE 3 Long-term survival of patients discharged from hospital following their first presentation to critical
care. p=0.008 medical versus surgical, p=0.001 medical versus obstetric, p=0.073 surgical versus obstetric.
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Long-term survival
The overall observed survival rates after critical care admission were 65% at 90 days, 55% at 1 year and
31% at 5 years. For the medical cohort, these survival rates were 55%, 41% and 23%, respectively (table 3).
The median (95% CI) survival time from first critical care admission was 17.9 months (546 (range
255–838) days) overall and 7.9 months (241 (54–428) days) for medical patients. For those patients
surviving to hospital discharge after first critical care admission, Kaplan–Meier analysis demonstrated
superior 1- and 5-year survival in the surgical and obstetric groups (90% and 100% at 1 year, 63% and
94% at 5 years) when compared with the medical group (69% and 37%, respectively; p=0.012 medical
versus surgical, p=0.004 medical versus obstetric, p=0.07 surgical versus obstetric) (figure 3).
Functional outcomes in critical care survivors
Comparison of the mean (95% CI) ISWD prior to admission versus nearest 6- and 12-months’ follow-up
in hospital survivors for the medical group showed no statistical difference on paired samples t-testing
(baseline 233 m (95% CI 186–281) versus 6-months follow-up 206 m (95% CI 164–248), p=0.063 or versus
12-months follow-up 227 m (95% CI 181–273), p=0.941). This lack of change was also observed across the
surgical group, while there were insufficient data available for the obstetric group. Similarly, there was no
significant difference in the WHO FC before and after critical care admission in the medical group using
Wilcoxon signed-rank test (median (range) WHO FC 3 (2–4) at both time-points, p=0.197). This lack of
change was also observed across the obstetric and surgical populations.
Discussion
To our knowledge this is the largest study, to date, of patients with well-characterised PH who have been
treated in a critical care setting. We have demonstrated that medical patients have more severely abnormal
physiological and laboratory markers than surgical/obstetric patients and have poorer short- and longer
term prognosis. We have also identified several important markers of in-hospital mortality in patients
admitted due to medical decompensation. Although only a very small proportion of patients receiving
invasive ventilation were discharged from hospital, 50% of patients who required RRT left hospital alive.
Finally, we were unable to find a significant difference between pre-admission and post-discharge exercise
capacity and WHO FC, suggesting that patients who survive to hospital discharge may regain a similar
functional state following a critical care admission.
Survival
SZTRYMF et al. [13] previously studied 46 PAH patients with right heart failure and observed 41% ICU
mortality. Subsequently, HUYNH et al. [11] reported 30% ICU and 40% 6-month mortality in 99 PH
patients while KURZYNA et al. [18] and CAMPO et al. [19] observed 32% and 48% in-hospital mortalities in
their studies of 37 and 29 critically ill PH patients, respectively. SAYDAIN et al. [12] studied 53 patients
(largely composed of PH secondary to lung or left heart disease) and observed hospital mortality of 26%
to 36%, while TSAPENKO et al. [14] reported hospital mortality of 48% in a PH patient cohort largely
secondary to lung disease. Critical care (28%) and in-hospital (41%) mortality of our patients admitted to
critical care for medical reasons are consistent with these previous reports and highlight the significant
mortality associated with decompensation in patients with pre-existing PH. Of note, all admissions to
critical care were deemed appropriate following a multidisciplinary discussion between PH and ICU
physicians. Survival figures therefore reflect a carefully selected patient cohort, rather than an
undifferentiated PH population. Although only 38% of medical patients were admitted due to isolated
right heart failure (i.e. progressive right heart failure with no obvious precipitant), the majority of other
medical patients had either a precipitant of right heart failure (e.g. sepsis, respiratory failure or arrhythmia)
or a complication of right heart failure (e.g. renal failure).
Hospital mortality for surgical and obstetric patients was significantly lower (6% and 8%) than in medical
patients and is in keeping with previous reports [8, 9, 20]. PRICE et al. [8] studied 28 patients with PH who
underwent non-cardiac and non-obstetric surgery and observed a peri-operative death rate of 7%. MEYER
et al. [9] subsequently studied 114 patients with PAH who underwent non-cardiac and non-obstetric
surgery and reported an overall mortality of 3.5%, with emergency surgery being associated with a
significantly higher death rate than planned surgery (15% versus 2%). Despite outcomes in pregnancy
having improved over recent years, the peripartum period is recognised as posing a significant risk and
two patients with severe PAH (one of whom presented following delivery) died post-partum despite
aggressive management [10, 20].
Prognostic markers
RV failure in decompensated PH leads to low cardiac output (forward failure) and impaired venous return
(backward failure) [21, 22]. We identified a number of significant prognostic markers at univariate analysis
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which reflect these two processes: low cardiac output: acid–base disturbance (base excess, lactate); impaired
venous return: central venous pressure and hepatic congestion (bilirubin); and a combination of the
two processes: renal impairment (urea, creatinine). We also identified several independent additional
prognostic markers: lower SpO2/FiO2 ratio, serum sodium, and platelet count and higher age, lactate and
APACHE II score.
Hypoxia in PH results in worsened pulmonary vasoconstriction with subsequent detrimental effects on
RV function [21, 23]. Hypoxaemia at rest or during exercise has been shown to be predictive of lower
survival duration in stable PAH patients [24]. Our data suggests that this observation can be extended to
the critical care population, where lower SpO2/FiO2 ratios at critical care admission indicated higher hospital
mortality. Our observation that lower serum sodium predicted acute mortality is consistent with reports of
reduced longer term survival in stable PH patients [25] and increased short-term mortality in hospitalised
PAH patients with right ventricular failure [13, 19]. Hyponatraemia is a hallmark of cardiorenal syndrome
and may result from both low cardiac output and congestive RV failure [26]. The present study is the first
to report prognostic utility of the admission platelet count in ICU patients. Previous reports in stable
patients have described an association with right atrial pressure and mixed venous oxygen saturations [27]
and demonstrated that the degree of thrombocytopenia may be an independent predictor of 1-year
survival in patients with severe PH [28]. Thrombocytopenia may occur due to reduced thrombopoietin
production, bone marrow suppression, increased sequestration and platelet activation, aggregation from
vascular stasis in an altered circulatory environment and the effects of both targeted therapies and
associated underlying disease processes [29, 30]. We were unable to distinguish between patients who had
received intravenous prostanoid therapy on the ward prior to critical care admission from those who had
commenced it after admission to critical care and so could not draw any conclusions regarding its possible
contribution to the observed thrombocytopenia.
Previous studies have demonstrated the prognostic utility of acute physiological scores in PH patients on
admission, including APACHE II [11], SAPS II [13] or SOFA scores [12]. APACHE II is comprised of age
plus 12 physiological and laboratory measurements: arterial oxygen tension; temperature; mean arterial
pressure; pH; heart rate; respiratory rate; sodium, potassium and creatinine levels; haematocrit; white blood
cell count; and Glasgow Coma Scale. Many of these parameters were predictors of outcome at univariate
analysis. When APACHE II was excluded from the multivariate model, age, serum sodium, platelet count,
SpO2/FiO2 ratio and lactate were independent predictors, suggesting that these components of APACHE II
are of particular importance. A simple exploratory scoring system which can be quickly calculated at the
bedside in medical patients using the five independent single risk factors, OPALS (oxygen (SpO2/FiO2) ⩽185,
platelets ⩽196×109·L−1, age ⩾37.5 years, lactate ⩾2.45 mmol·L−1, sodium ⩽130.5 mmol·L−1), identified
patients at increasing risk of mortality. The numbers of patients with 0 or 5 adverse factors was, however,
very low and validation and further comparison with APACHE II in other large cohorts is required.
It was interesting to note that although markers of acute physiological deterioration predicted critical care
outcomes, pulmonary haemodynamics did not. This may reflect the fact that right heart catheterisation is
not repeated at routine intervals and so the most recent pulmonary haemodynamics may have been
obtained some time before the critical care admission.
Interventions
The need for advanced organ support in the medical cohort was associated with poorer survival,
consistent with more severely unwell patients requiring these treatments. Of note, out of nine medical
patients who received invasive ventilation, only three (33%) survived to critical care discharge and a single
patient (11%) survived to hospital discharge, suggesting that invasive ventilation is likely appropriate only
in selected cases. It is interesting to observe that 50% of patients who required RRT survived to hospital
discharge. HADDAD et al. [31] previously identified acute kidney injury in PAH patients hospitalised with
right heart failure as an important predictor of poor outcome. Acute kidney injury in patients with PH is
associated with renal venous congestion [32]; RRT could potentially offer significant beneficial effects on
management of volume status and right ventricular function in PH patients [33, 34]. There are very
limited data describing the use of acute RRT in PH patients [31]. Our data would suggest that RRT should
be considered in patients with acute decompensation.
Longer term survival and functional outcome
This is the first study to report longer term outcomes in PH patients admitted to a critical care unit.
1-year survival of 40.7% in medical patients suggests that critical care intervention may enable additional
quantity of life in a proportion of patients. Functional follow-up data (WHO FC and ISWD) of survivors
suggests that many survivors to discharge regain similar levels of functioning as compared with their
pre-admission state.
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Limitations
Due to the long timescale of the study there were missing data in variables relating to pre-admission
investigations, making firm conclusions regarding their prognostic importance, or lack of, difficult. The
single-centre and retrospective nature of the study design may impede generalisability of the findings.
Nevertheless, these data represent long-term experience from a large PH referral centre and our findings
are generally consistent with previous smaller studies [11, 13, 19].
Conclusion
Medical patients admitted to a critical care unit because of acute decompensation have more severe
physiological and laboratory perturbations and poorer survival than patients admitted following surgical or
obstetric interventions. Higher APACHE II score, age and lactate, and lower SpO2/FiO2, platelet count and
sodium level are important predictors of hospital discharge. Invasive ventilation in medically
decompensated patients is associated with a low chance of hospital survival whereas 50% of patients
receiving RRT leave hospital alive. In patients who survive to discharge, pre-admission levels of functional
status may be achieved. These data have clinical utility in guiding decisions regarding critical care
admission and intensity of interventions in patients with known PH.
Conflict of interest: K. Bauchmuller has nothing to disclose. R. Condliffe reports honoraria for lecturing and advisory
boards from Actelion and MSD outside the submitted work. J. Southern has nothing to disclose. C. Billings has nothing
to disclose. A. Charalampopoulos has nothing to disclose. C.A. Elliot received lecture and consultancy fees from
Actelion, Bayer and GSK pharmaceuticals. A. Hameed has nothing to disclose. D.G. Kiely reports grants, personal fees
and other support from Actelion, Bayer and GSK, and personal fees and other support from MSD, outside the
submitted work. I. Sabroe has nothing to disclose. A.A.R. Thompson reports an Intermediate Clinical Fellowship (FS/
18/13/3328) from the British Heart Foundation during the conduct of the study and support for travel to attend
educational meetings from Actelion Pharmaceuticals Ltd outside the submitted work. A. Raithatha has nothing to
disclose. G.H. Mills has nothing to disclose.
Support statement: This study was supported by British Heart Foundation grant FS/18/13/3328. Funding information
for this article has been deposited with the Crossref Funder Registry.
References
1 Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary
hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European
Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European
Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Eur Heart J 2016; 37: 67–119.
2 Kiely DG, Elliot CA, Sabroe I, et al. Pulmonary hypertension: diagnosis and management. BMJ 2013; 346: f2028.
3 Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA Education 2017; 17: 228–234.
4 Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic
thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 1122–1127.
5 Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated
pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.
6 Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in
patients with pulmonary hypertension. Eur Respir J 2019; 53: 1801906.
7 Price LC, Dimopoulos K, Marino P, et al. The CRASH report: emergency management dilemmas facing acute
physicians in patients with pulmonary arterial hypertension. Thorax 2017; 72: 1035–1045.
8 Price LC, Montani D, Jais X, et al. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary
hypertension. Eur Respir J 2010; 35: 1294–1302.
9 Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH:
an international prospective survey. Eur Respir J 2013; 41: 1302–1307.
10 Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among
women with pulmonary arterial hypertension? Eur Heart J 2009; 30: 256–265.
11 Huynh TN, Weigt SS, Sugar CA, et al. Prognostic factors and outcomes of patients with pulmonary hypertension
admitted to the intensive care unit. J Crit Care 2012; 27: 739.e7–13.
12 Saydain G, Awan A, Manickam P, et al. Pulmonary hypertension an independent risk factor for death in intensive
care unit: correlation of hemodynamic factors with mortality. Clin Med Insights Circ Respir Pulm Med 2015; 9:
27–33.
13 Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial
hypertension. Eur Respir J 2010; 35: 1286–1293.
14 Tsapenko MV, Herasevich V, Mour GK, et al. Severe sepsis and septic shock in patients with pre-existing
non-cardiac pulmonary hypertension: contemporary management and outcomes. Crit Care Resusc 2013; 15:
103–109.
15 Rush B, Biagioni BJ, Berger L, et al. Mechanical ventilation outcomes in patients with pulmonary hypertension in
the United States: a national retrospective cohort analysis. J Intensive Care Med. 2017; 32: 588–592.
16 Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension
Identified at a REferral centre. Eur Respir J 2012; 39: 945–955.
17 Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll
Cardiol 2013; 62: D34–D41.
18 Kurzyna M, Zylkowska J, Fijalkowska A, et al. Characteristics and prognosis of patients with decompensated right
ventricular failure during the course of pulmonary hypertension. Kardiol Pol 2008; 66: 1033–1039.
https://doi.org/10.1183/23120541.00046-2021 11
CRITICAL CARE | K. BAUCHMULLER ET AL.
19 Campo A, Mathai SC, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial
hypertension. Eur Respir J 2011; 38: 359–367.
20 Kiely DG, Condliffe R, Webster V, et al. Improved survival in pregnancy and pulmonary hypertension using a
multiprofessional approach. BJOG 2010; 117: 565–574.
21 Hoeper MM, Granton J. Intensive care unit management of patients with severe pulmonary hypertension and
right heart failure. Am J Respir Crit Care Med 2011; 184: 1114–1124.
22 Wilcox SR, Kabrhel C, Channick RN. Pulmonary hypertension and right ventricular failure in emergency
medicine. Ann Emerg Med 2015; 66: 619–628.
23 Greyson CR. The right ventricle and pulmonary circulation: basic concepts. Rev Esp Cardiol 2010; 63: 81–95.
24 Khirfan G, Naal T, Abuhalimeh B, et al. Hypoxemia in patients with idiopathic or heritable pulmonary arterial
hypertension. PLoS One 2018; 13: e0191869.
25 Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary
arterial hypertension. Am J Respir Crit Care Med 2008; 177: 1364–1369.
26 Jentzer JC, Mathier MA. Pulmonary hypertension in the intensive care unit. J Intensive Care Med 2016; 31:
369–385.
27 Chin KM, Channick RN, de Lemos JA, et al. Hemodynamics and epoprostenol use are associated with
thrombocytopenia in pulmonary arterial hypertension. Chest 2009; 135: 130–136.
28 Mojadidi MK, Goodman-Meza D, Eshtehardi P, et al. Thrombocytopenia is an independent predictor of mortality
in pulmonary hypertension. Heart Lung 2014; 43: 569–573.
29 Remkova A, Simkova I, Valkovicova T, et al. Platelet abnormalities in adults with severe pulmonary arterial
hypertension related to congenital heart defects (Eisenmenger syndrome). Blood Coagul Fibrinolysis 2016; 27:
925–929.
30 Vrigkou E, Tsangaris I, Bonovas S, et al. Platelet and coagulation disorders in newly diagnosed patients with
pulmonary arterial hypertension. Platelets 2019; 30: 646–651.
31 Haddad F, Fuh E, Peterson T, et al. Incidence, correlates, and consequences of acute kidney injury in patients with
pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Card Fail 2011; 17: 533–539.
32 Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with
renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872–878.
33 Ventetuolo CE, Klinger JR. Management of acute right ventricular failure in the intensive care unit. Ann Am
Thorac Soc 2014; 11: 811–822.
34 Olsson KM, Halank M, Egenlauf B, et al. Decompensated right heart failure, intensive care and perioperative
management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus
Conference 2018. Int J Cardiol 2018; 272S: 46–52.
https://doi.org/10.1183/23120541.00046-2021 12
CRITICAL CARE | K. BAUCHMULLER ET AL.
